Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

科研成果: 期刊稿件文章同行评审

133 引用 (Scopus)
源语言英语
页(从-至)391-402
页数12
期刊Kidney International
103
2
DOI
出版状态已出版 - 2月 2023

!!!ASJC Scopus Subject Areas

  • 肾脏学

指纹

探究 'Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy' 的科研主题。它们共同构成独一无二的指纹。

引用此